Food security: In a 21 October report, Britain's national academy of science, the Royal Society, urged more investment in agricultural research to stave off a potential global food crisis. The nation should invest at least £2 billion (US$3.3 billion) over 10 years to fund a research programme studying global food crop security, the report said. Genetic modification of crops, strategic plant breeding and new farming management practices would all be needed to increase yields in a sustainable way.
Energy funding:
The US Congress has passed a $33.5-billion energy and water spending bill for fiscal year 2010. The bill includes $27.1 billion for the Department of Energy, a 1% increase over the previous year. Of that, $2.2 billion will go to energy-efficiency and renewable-energy projects, a $314 million increase from the previous year. But only three of eight proposed 'energy-research hubs' -an idea pushed for by energy secretary Steven Chuare supported, at $22 million each. The bill gives hydrogen and fuel-cell programmes In the department of silver linings, a glimmer for the biotechnology sector: the average share price of 360 US biotech companies tracked by EvaluatePharma has risen by 203% since the start of the year. Globally, the year-to-date rise is 163%, in the 590 biotech and speciality companies followed by the London-based research firm. Third-quarter results also show biotech outpacing the pharmaceutical sector in share-price rises (see chart). The rise is not entirely unexpected. Biotech share prices had almost nowhere to go but up, after risk-averse investors fled the market a year ago at the height of the financial meltdown. "Biotech stocks in particular were hammered at end of 2008, so you are starting from a really low base," says Christian Glennie, the senior editorial analyst at EvaluatePharma.
Signs of a true revival may be better gauged by the number of initial public offerings (IPOs apologized in her resignation letter for her "unprofessional" behaviour.
and could eventually serve as a base for 1,500 scientists working for early-stage biotech companies. Initial funding has been provided by the UK government (£16.7 million [US$27 million]), the Wellcome Trust (£6 million), GSK (£11 million) and the East of England Development Agency (£4 million) -who say they expect eventual investment in the campus to approach £170 million.
